Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Intas Pharmaceuticals Ltd.

'Affordable' Russian Rituximab Biosimilar On Course In India

Biocad’s biosimilar rituximab appears headed for an Indian debut amid significant competition but the Russian firm appears confident that its “full-cycle production” will give it an edge and also facilitate a flexible pricing policy.

Biosimilars Approvals

REMS Class-Action Lawsuit Against Celgene Is First By Patients

Patients For Affordable Drugs Founder David Mitchell alleges Celgene's unlawful delay tactics like REMS obstruction kept generic versions of Thalomid and Revlimid off the market, forcing plaintiffs to pay higher costs.

Drug Safety Generic Drugs

Intas Allays Concerns Around Lucentis Biosimilar In India

Intas Pharmaceuticals has claimed that certain adverse events reported with its Lucentis biosimilar were not caused by “qualitative aspects” of the product and that physicians have since “very satisfactorily” used subsequent batches of the vascular endothelial growth factor inhibitor in India.

Commercial Biosimilars

Taking Biosimilars Down A PEG: Why Copying Neulasta Isn’t So Easy

Biosimilar sponsors are 0-3 so far in attempts to win US FDA approval for copies of Amgen’s pegfilgrastim (Neulasta). FDA’s recent review of a novel clotting factor formulation offers a clue why it is turning out to be harder than it seems to copy a pegylated protein.

Advisory Committees Biosimilars
See All

Company Information

  • Industry
  • Medical Devices
    • Consumables, Central Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Engineering & Research Associates Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • SEBRA
  • Senior Management
  • Roger Vogel, Pres. & CEO
    Alan Smith, CFO
    Bill Thomasson, COO
  • Contact Info
  • SEBRA
    Phone: (520) 881-6555
    100 N. Tucson Blvd.
    Tucson, AZ 85716
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register